Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2000 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/26202 http://dx.doi.org/10.1046/j.1469-0691.2000.00011.x |
Resumo: | Objective To study the influence of soluble tumour necrosis factor (TNF) receptors (sTNFR) on bioactivity; and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis (Kala-azar) and to examine the association between circulating levels of sTNFR type I and type IT with clinical manifestations of the disease.Methods Ten patients with Kala-azar were enrolled. Plasma samples for TNF-alpha and sTNFR were obtained on days 0, 7 and 21-28 of antimonial therapy. Bioactivity of TNF-alpha was measured by cytotoxicity to L-929 cells and immunoreactivity by enzyme-linked immunosorbent assay (ELISA). sTNFR-I and sTNFR-II were measured by ELISA.Results Measured by ELISA, TNF-alpha was detected at baseline in all patients (range from 22.3 to 163 pg/mL) and showed a linear decline over time on therapy (r = -0.49, P = 0.007). in contrast, when measured by cytotoxicity assay, TNF-alpha was detected in only one patient at baseline (193 pg/mL) and in four patients at the end of therapy (38.7, 95, 133 and 232 pg/mL) and there was no linear association between TNF-alpha. and duration of therapy (r = -0.18, P = 0.45). sTNFR-I and sTNFR-II were detected in all patients before therapy. There was a strong positive correlation between plasma concentrations of sTNFR-I and sTNFR-II (r = 0.8, P = 0.006). Levels of sTNFR-I and sTNFR-II declined exponentially with time on therapyConclusions We concluded that sTNFR-I and sTNFR-II are related to disease activity in patients with Kala-azar and that these circulating receptors may interfere with the biological activity of TNF-alpha in patients with Kala-azar. |
id |
UFSP_3ec602ada24728a1f388abd5575a9e51 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/26202 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Medeiros, Iara Marques de [UNIFESP]Reed, S.Castelo Filho, Adauto [UNIFESP]Salomão, Reinaldo [UNIFESP]Universidade Federal de São Paulo (UNIFESP)Univ Fed Rio Grande NorteInfect Dis Res Inst2016-01-24T12:30:57Z2016-01-24T12:30:57Z2000-01-01Clinical Microbiology and Infection. Oxford: Blackwell Science Ltd, v. 6, n. 1, p. 34-37, 2000.1198-743Xhttp://repositorio.unifesp.br/handle/11600/26202http://dx.doi.org/10.1046/j.1469-0691.2000.00011.x10.1046/j.1469-0691.2000.00011.xWOS:000086861000007Objective To study the influence of soluble tumour necrosis factor (TNF) receptors (sTNFR) on bioactivity; and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis (Kala-azar) and to examine the association between circulating levels of sTNFR type I and type IT with clinical manifestations of the disease.Methods Ten patients with Kala-azar were enrolled. Plasma samples for TNF-alpha and sTNFR were obtained on days 0, 7 and 21-28 of antimonial therapy. Bioactivity of TNF-alpha was measured by cytotoxicity to L-929 cells and immunoreactivity by enzyme-linked immunosorbent assay (ELISA). sTNFR-I and sTNFR-II were measured by ELISA.Results Measured by ELISA, TNF-alpha was detected at baseline in all patients (range from 22.3 to 163 pg/mL) and showed a linear decline over time on therapy (r = -0.49, P = 0.007). in contrast, when measured by cytotoxicity assay, TNF-alpha was detected in only one patient at baseline (193 pg/mL) and in four patients at the end of therapy (38.7, 95, 133 and 232 pg/mL) and there was no linear association between TNF-alpha. and duration of therapy (r = -0.18, P = 0.45). sTNFR-I and sTNFR-II were detected in all patients before therapy. There was a strong positive correlation between plasma concentrations of sTNFR-I and sTNFR-II (r = 0.8, P = 0.006). Levels of sTNFR-I and sTNFR-II declined exponentially with time on therapyConclusions We concluded that sTNFR-I and sTNFR-II are related to disease activity in patients with Kala-azar and that these circulating receptors may interfere with the biological activity of TNF-alpha in patients with Kala-azar.Universidade Federal de São Paulo, Escola Paulista Med, Div Infect Dis, UNIFESP, BR-04023900 São Paulo, SP, BrazilUniv Fed Rio Grande Norte, BR-59072970 Natal, RN, BrazilInfect Dis Res Inst, Seattle, WA USAUniversidade Federal de São Paulo, Escola Paulista Med, Div Infect Dis, UNIFESP, BR-04023900 São Paulo, SP, BrazilWeb of Science34-37engBlackwell Science LtdClinical Microbiology and Infectionvisceral leishmaniasistumour necrosis factorsoluble tumour necrosis factor receptorsTNFRCirculating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/262022022-06-02 09:06:00.291metadata only accessoai:repositorio.unifesp.br:11600/26202Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652022-06-02T12:06Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis |
title |
Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis |
spellingShingle |
Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis Medeiros, Iara Marques de [UNIFESP] visceral leishmaniasis tumour necrosis factor soluble tumour necrosis factor receptor sTNFR |
title_short |
Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis |
title_full |
Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis |
title_fullStr |
Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis |
title_full_unstemmed |
Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis |
title_sort |
Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis |
author |
Medeiros, Iara Marques de [UNIFESP] |
author_facet |
Medeiros, Iara Marques de [UNIFESP] Reed, S. Castelo Filho, Adauto [UNIFESP] Salomão, Reinaldo [UNIFESP] |
author_role |
author |
author2 |
Reed, S. Castelo Filho, Adauto [UNIFESP] Salomão, Reinaldo [UNIFESP] |
author2_role |
author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) Univ Fed Rio Grande Norte Infect Dis Res Inst |
dc.contributor.author.fl_str_mv |
Medeiros, Iara Marques de [UNIFESP] Reed, S. Castelo Filho, Adauto [UNIFESP] Salomão, Reinaldo [UNIFESP] |
dc.subject.eng.fl_str_mv |
visceral leishmaniasis tumour necrosis factor soluble tumour necrosis factor receptor sTNFR |
topic |
visceral leishmaniasis tumour necrosis factor soluble tumour necrosis factor receptor sTNFR |
description |
Objective To study the influence of soluble tumour necrosis factor (TNF) receptors (sTNFR) on bioactivity; and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis (Kala-azar) and to examine the association between circulating levels of sTNFR type I and type IT with clinical manifestations of the disease.Methods Ten patients with Kala-azar were enrolled. Plasma samples for TNF-alpha and sTNFR were obtained on days 0, 7 and 21-28 of antimonial therapy. Bioactivity of TNF-alpha was measured by cytotoxicity to L-929 cells and immunoreactivity by enzyme-linked immunosorbent assay (ELISA). sTNFR-I and sTNFR-II were measured by ELISA.Results Measured by ELISA, TNF-alpha was detected at baseline in all patients (range from 22.3 to 163 pg/mL) and showed a linear decline over time on therapy (r = -0.49, P = 0.007). in contrast, when measured by cytotoxicity assay, TNF-alpha was detected in only one patient at baseline (193 pg/mL) and in four patients at the end of therapy (38.7, 95, 133 and 232 pg/mL) and there was no linear association between TNF-alpha. and duration of therapy (r = -0.18, P = 0.45). sTNFR-I and sTNFR-II were detected in all patients before therapy. There was a strong positive correlation between plasma concentrations of sTNFR-I and sTNFR-II (r = 0.8, P = 0.006). Levels of sTNFR-I and sTNFR-II declined exponentially with time on therapyConclusions We concluded that sTNFR-I and sTNFR-II are related to disease activity in patients with Kala-azar and that these circulating receptors may interfere with the biological activity of TNF-alpha in patients with Kala-azar. |
publishDate |
2000 |
dc.date.issued.fl_str_mv |
2000-01-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T12:30:57Z |
dc.date.available.fl_str_mv |
2016-01-24T12:30:57Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Clinical Microbiology and Infection. Oxford: Blackwell Science Ltd, v. 6, n. 1, p. 34-37, 2000. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/26202 http://dx.doi.org/10.1046/j.1469-0691.2000.00011.x |
dc.identifier.issn.none.fl_str_mv |
1198-743X |
dc.identifier.doi.none.fl_str_mv |
10.1046/j.1469-0691.2000.00011.x |
dc.identifier.wos.none.fl_str_mv |
WOS:000086861000007 |
identifier_str_mv |
Clinical Microbiology and Infection. Oxford: Blackwell Science Ltd, v. 6, n. 1, p. 34-37, 2000. 1198-743X 10.1046/j.1469-0691.2000.00011.x WOS:000086861000007 |
url |
http://repositorio.unifesp.br/handle/11600/26202 http://dx.doi.org/10.1046/j.1469-0691.2000.00011.x |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Clinical Microbiology and Infection |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
34-37 |
dc.publisher.none.fl_str_mv |
Blackwell Science Ltd |
publisher.none.fl_str_mv |
Blackwell Science Ltd |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1802764130542682112 |